The promise and pitfalls of molecular testing in oncology

DR CHRIS GAJ | August 30, 2019 | 331 views

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients. Central to this is how to use the large amounts of genetic data now available. Dr Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets. Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual ‘Lazarus-like’ responses to erlotinib, but overall effectiveness was moderate in unselected populations.

Spotlight

Viwit Pharmaceuticals

Viwit Pharmaceutical Co., Ltd. (Viwit), founded in 2006, is a fast-growing research-based pharmaceutical healthcare company dedicated to the development, manufacture and marketing of innovative products in the fields of Finished Dosage Formulations, Active Pharmaceutical Ingredients and Fine Chemicals. Viwit manufactures all the products based on company’s core technologies, and is dedicated to serve customers for their greater success and healthier living.

OTHER ARTICLES
BUSINESS INSIGHTS

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | June 30, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | September 29, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | August 9, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Viwit Pharmaceuticals

Viwit Pharmaceutical Co., Ltd. (Viwit), founded in 2006, is a fast-growing research-based pharmaceutical healthcare company dedicated to the development, manufacture and marketing of innovative products in the fields of Finished Dosage Formulations, Active Pharmaceutical Ingredients and Fine Chemicals. Viwit manufactures all the products based on company’s core technologies, and is dedicated to serve customers for their greater success and healthier living.

Related News

Lantern Pharma’s Proprietary A.I. Platform Surpasses 450 Million Data Points Accelerating Oncology Drug Development and Drug Response Prediction

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue). RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes. Lantern is establishing collaborations and partnerships to expand the functionality of RADR®, including algorithms that can operate 200 to 300 percent faster than its existing algorithms, enabling the company to develop robust gene signatures that can be used to guide patient enrollment in trials and as a companion diagnostic (CDx). During the most recent data enrichment campaign, Lantern focused on significantly increasing the depth and amount of data for: non-small cell lung cancer, ovarian cancer, glioblastoma, and gliomas. Reaching this milestone of over 450 million curated data points for oncology drug development will bring greater precision and speed in helping Lantern with its objective of personalizing oncology therapy with reduced risk and cost.

Read More

Novartis appoints Elizabeth Barrett as Oncology Head

Novartis | January 11, 2018

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno Strigini who decided to retire from Novartis for personal reasons. Vasant (Vas) Narasimhan, designated CEO of Novartis, said: Liz is a highly accomplished and recognized oncology and people leader with an impressive record of building successful business organizations in the US, Europe and globally. She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities. Her long-time commercial pharma industry experience, marketing skills, and perspectives make Liz a great fit to further develop our oncology business.

Read More

Lantern Pharma’s Proprietary A.I. Platform Surpasses 450 Million Data Points Accelerating Oncology Drug Development and Drug Response Prediction

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue). RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes. Lantern is establishing collaborations and partnerships to expand the functionality of RADR®, including algorithms that can operate 200 to 300 percent faster than its existing algorithms, enabling the company to develop robust gene signatures that can be used to guide patient enrollment in trials and as a companion diagnostic (CDx). During the most recent data enrichment campaign, Lantern focused on significantly increasing the depth and amount of data for: non-small cell lung cancer, ovarian cancer, glioblastoma, and gliomas. Reaching this milestone of over 450 million curated data points for oncology drug development will bring greater precision and speed in helping Lantern with its objective of personalizing oncology therapy with reduced risk and cost.

Read More

Novartis appoints Elizabeth Barrett as Oncology Head

Novartis | January 11, 2018

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno Strigini who decided to retire from Novartis for personal reasons. Vasant (Vas) Narasimhan, designated CEO of Novartis, said: Liz is a highly accomplished and recognized oncology and people leader with an impressive record of building successful business organizations in the US, Europe and globally. She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities. Her long-time commercial pharma industry experience, marketing skills, and perspectives make Liz a great fit to further develop our oncology business.

Read More

Events